Plain-English translation of NCT06676527 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world study following patients with advanced kidney cancer who are being treated with vorolanib, a newer targeted medication that works by stopping tumor growth and blood vessel formation. The researchers will collect survival and safety information from patients already receiving this treatment and compare it to results from previous studies to better understand how well this medication works.
Kidney cancer patients whose initial treatment stops working need other options. This study aims to gather real-world evidence about how this medication performs outside of controlled research settings and whether it helps patients live longer and with fewer side effects.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will take vorolanib as prescribed by your doctor. The study team will collect information about your survival, how well the medication is working, and any side effects you experience through follow-up appointments and medical records. Some participants already receiving this medication will be tracked prospectively (going forward), while others whose treatment has ended will be analyzed retrospectively (looking back at past records).
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China
Sponsor
Jinling Hospital, China
Enrollment target
~39 participants
Started
September 2024
Primary completion
September 2026
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Le Qu, M. D.
Jinling Hospital, China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.